Product Description
BIIB021 is a novel, fully synthetic inhibitor of Hsp90 that binds competitively with geldanamycin in the ATP-binding pocket of Hsp90. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19372565/)
Mechanisms of Action: HSP90 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Breast Cancer|Gastrointestinal Stromal Tumors
Phase 1: Breast Cancer|Lymphoma|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 120BC101 | P1 |
Completed |
Breast Cancer |
2011-04-01 |
2019-03-21 |
||
| 120ST104 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2010-08-01 |
2019-03-19 |
Treatments |
|
| 120ST103 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2010-07-01 |
2019-03-18 |
Treatments |
|
| CNF2024-ST-05003 | P1 |
Completed |
Lymphoma |
2008-07-01 |
2019-03-21 |
Treatments |
|
| CNF2024-CLL-05002 | P1 |
Terminated |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2008-07-01 |
2019-03-21 |
Treatments |
|
| 2009-014796-51 | P2 |
Completed |
Breast Cancer |
2011-10-31 |
2022-03-13 |
Treatments |
|
| 120BC201 | P2 |
Completed |
Breast Cancer |
2011-10-01 |
2019-03-19 |
Treatments |
|
| 120GS201 | P2 |
Completed |
Gastrointestinal Stromal Tumors |
2010-04-01 |
2019-03-18 |